Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson sold 20,000 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $34.04, for a total transaction of $680,800.00. Following the completion of the transaction, the chief executive officer now owns 135,368 shares in the company, valued at $4,607,926.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ BOLD traded down $0.22 during trading on Thursday, reaching $33.88. The company had a trading volume of 6,313 shares, compared to its average volume of 333,850. Audentes Therapeutics Inc has a 52 week low of $17.95 and a 52 week high of $41.65. The stock has a market cap of $1.55 billion, a PE ratio of -9.96 and a beta of 1.70. The business’s 50 day moving average is $37.11.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.08) by $0.07. During the same quarter in the prior year, the company earned ($0.85) EPS. As a group, equities analysts anticipate that Audentes Therapeutics Inc will post -4.25 earnings per share for the current fiscal year.

A number of equities analysts have commented on the stock. Leerink Swann restated an “outperform” rating and issued a $48.00 price target (up from $37.00) on shares of Audentes Therapeutics in a research report on Wednesday, April 17th. Svb Leerink boosted their price target on shares of Audentes Therapeutics from $37.00 to $48.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. ValuEngine upgraded shares of Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 27th. Zacks Investment Research lowered shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Mizuho restated a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $39.99.

Several institutional investors and hedge funds have recently bought and sold shares of BOLD. Bank of New York Mellon Corp raised its stake in shares of Audentes Therapeutics by 19.1% during the fourth quarter. Bank of New York Mellon Corp now owns 152,232 shares of the biotechnology company’s stock worth $3,245,000 after buying an additional 24,462 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Audentes Therapeutics by 232.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 564,047 shares of the biotechnology company’s stock worth $12,025,000 after buying an additional 394,602 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Audentes Therapeutics by 16.8% during the fourth quarter. Geode Capital Management LLC now owns 394,455 shares of the biotechnology company’s stock worth $8,409,000 after buying an additional 56,856 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Audentes Therapeutics by 34.5% during the fourth quarter. Legal & General Group Plc now owns 6,632 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,700 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Audentes Therapeutics by 123.1% during the fourth quarter. Deutsche Bank AG now owns 145,324 shares of the biotechnology company’s stock worth $3,097,000 after buying an additional 80,199 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: What is the price-sales ratio?

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.